APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Avastin (Bevacizumab) Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Avastin (Bevacizumab) Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173968440330 December 2025198 pages

Choose your research edition.

Industry ResearchAvastin (Bevacizumab) Biosimilars Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Avastin (Bevacizumab) Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Avastin (Bevacizumab) Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Avastin (Bevacizumab) Biosimilars Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Avastin (Bevacizumab) Biosimilars Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Avastin (Bevacizumab) Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Avastin (Bevacizumab) Biosimilars include Biocad, Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero, Kirin Biologics and MAbxience, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Avastin (Bevacizumab) Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Avastin (Bevacizumab) Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Avastin (Bevacizumab) Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Avastin (Bevacizumab) Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Avastin (Bevacizumab) Biosimilars Segment by Company

Biocad

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero

Kirin Biologics

MAbxience

PharmaPraxis

PlantForm

Samsung Bioepis

Sartorius

Amgen

BeiGene

Bayer

TOT BIOPHARM

Henlius

Pfizer

Eli Lilly

Roche

Luye Pharmaceutical

Mylan

Qilu Pharmaceutical

Innovent

Avastin (Bevacizumab) Biosimilars Segment by Type

Cancers

AMD

Avastin (Bevacizumab) Biosimilars Segment by Application

Hospitals

Clinics

Others

Avastin (Bevacizumab) Biosimilars Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avastin (Bevacizumab) Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Avastin (Bevacizumab) Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avastin (Bevacizumab) Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Avastin (Bevacizumab) Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Avastin (Bevacizumab) Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Avastin (Bevacizumab) Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Avastin (Bevacizumab) Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Avastin (Bevacizumab) Biosimilars Industry Trends Table 2. Avastin (Bevacizumab) Biosimilars Industry Drivers Table 3. Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges Table 4. Avastin (Bevacizumab) Biosimilars Industry Restraints Table 5. Global Avastin (Bevacizumab) Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Avastin (Bevacizumab) Biosimilars Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Manufacturers Table 9. Global Avastin (Bevacizumab) Biosimilars Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Avastin (Bevacizumab) Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Avastin (Bevacizumab) Biosimilars Manufacturers, Product Type & Application Table 13. Global Avastin (Bevacizumab) Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Avastin (Bevacizumab) Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cancers Table 17. Major Manufacturers of AMD Table 18. Global Avastin (Bevacizumab) Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2026) & (K Units) Table 20. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2027-2032) & (K Units) Table 21. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2026) Table 22. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2027-2032) Table 23. Global Avastin (Bevacizumab) Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2026) & (K Units) Table 25. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2027-2032) & (K Units) Table 26. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2026) Table 27. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Others Table 31. Global Avastin (Bevacizumab) Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2026) & (K Units) Table 33. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2027-2032) & (K Units) Table 34. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2026) Table 35. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2027-2032) Table 36. Global Avastin (Bevacizumab) Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2026) & (K Units) Table 38. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2027-2032) & (K Units) Table 39. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2026) Table 40. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2027-2032) Table 41. Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2026) & (K Units) Table 43. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2021-2026) Table 44. Global Avastin (Bevacizumab) Biosimilars Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Avastin (Bevacizumab) Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 48. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 49. Europe Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 51. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 58. Global Avastin (Bevacizumab) Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2021-2026) Table 62. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2027-2032) Table 63. Biocad Company Information Table 64. Biocad Business Overview Table 65. Biocad Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio Table 67. Biocad Recent Development Table 68. Biocon Company Information Table 69. Biocon Business Overview Table 70. Biocon Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio Table 72. Biocon Recent Development Table 73. Cadila Pharmaceuticals Company Information Table 74. Cadila Pharmaceuticals Business Overview Table 75. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio Table 77. Cadila Pharmaceuticals Recent Development Table 78. Centus Company Information Table 79. Centus Business Overview Table 80. Centus Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Centus Avastin (Bevacizumab) Biosimilars Product Portfolio Table 82. Centus Recent Development Table 83. Dr Reddy's Company Information Table 84. Dr Reddy's Business Overview Table 85. Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio Table 87. Dr Reddy's Recent Development Table 88. Genentech Company Information Table 89. Genentech Business Overview Table 90. Genentech Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio Table 92. Genentech Recent Development Table 93. Hetero Company Information Table 94. Hetero Business Overview Table 95. Hetero Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio Table 97. Hetero Recent Development Table 98. Kirin Biologics Company Information Table 99. Kirin Biologics Business Overview Table 100. Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio Table 102. Kirin Biologics Recent Development Table 103. MAbxience Company Information Table 104. MAbxience Business Overview Table 105. MAbxience Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio Table 107. MAbxience Recent Development Table 108. PharmaPraxis Company Information Table 109. PharmaPraxis Business Overview Table 110. PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 112. PharmaPraxis Recent Development Table 113. PlantForm Company Information Table 114. PlantForm Business Overview Table 115. PlantForm Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio Table 117. PlantForm Recent Development Table 118. Samsung Bioepis Company Information Table 119. Samsung Bioepis Business Overview Table 120. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 122. Samsung Bioepis Recent Development Table 123. Sartorius Company Information Table 124. Sartorius Business Overview Table 125. Sartorius Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 127. Sartorius Recent Development Table 128. Amgen Company Information Table 129. Amgen Business Overview Table 130. Amgen Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio Table 132. Amgen Recent Development Table 133. BeiGene Company Information Table 134. BeiGene Business Overview Table 135. BeiGene Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio Table 137. BeiGene Recent Development Table 138. Bayer Company Information Table 139. Bayer Business Overview Table 140. Bayer Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 142. Bayer Recent Development Table 143. TOT BIOPHARM Company Information Table 144. TOT BIOPHARM Business Overview Table 145. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio Table 147. TOT BIOPHARM Recent Development Table 148. Henlius Company Information Table 149. Henlius Business Overview Table 150. Henlius Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 152. Henlius Recent Development Table 153. Pfizer Company Information Table 154. Pfizer Business Overview Table 155. Pfizer Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 157. Pfizer Recent Development Table 158. Eli Lilly Company Information Table 159. Eli Lilly Business Overview Table 160. Eli Lilly Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio Table 162. Eli Lilly Recent Development Table 163. Roche Company Information Table 164. Roche Business Overview Table 165. Roche Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Roche Avastin (Bevacizumab) Biosimilars Product Portfolio Table 167. Roche Recent Development Table 168. Luye Pharmaceutical Company Information Table 169. Luye Pharmaceutical Business Overview Table 170. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 171. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 172. Luye Pharmaceutical Recent Development Table 173. Mylan Company Information Table 174. Mylan Business Overview Table 175. Mylan Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 176. Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio Table 177. Mylan Recent Development Table 178. Qilu Pharmaceutical Company Information Table 179. Qilu Pharmaceutical Business Overview Table 180. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 181. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 182. Qilu Pharmaceutical Recent Development Table 183. Innovent Company Information Table 184. Innovent Business Overview Table 185. Innovent Avastin (Bevacizumab) Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 186. Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio Table 187. Innovent Recent Development Table 188. Key Raw Materials Table 189. Raw Materials Key Suppliers Table 190. Avastin (Bevacizumab) Biosimilars Distributors List Table 191. Avastin (Bevacizumab) Biosimilars Customers List Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Avastin (Bevacizumab) Biosimilars Product Image Figure 2. Global Avastin (Bevacizumab) Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Avastin (Bevacizumab) Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Avastin (Bevacizumab) Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Avastin (Bevacizumab) Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Avastin (Bevacizumab) Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cancers Image Figure 9. AMD Image Figure 10. Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Avastin (Bevacizumab) Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2032) Figure 13. Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Others Image Figure 19. Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Avastin (Bevacizumab) Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2032) Figure 22. Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2032) Figure 25. North America Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2021-2032) Figure 27. U.S. Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2021-2032) Figure 32. Germany Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2021-2032) Figure 39. China Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2021-2032) Figure 47. Brazil Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Avastin (Bevacizumab) Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Avastin (Bevacizumab) Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Figure 58. North America Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Figure 60. Europe Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Avastin (Bevacizumab) Biosimilars Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Avastin (Bevacizumab) Biosimilars Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cancers
  • AMD
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Biocad
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero
  • Kirin Biologics
  • MAbxience
  • PharmaPraxis
  • PlantForm
  • Samsung Bioepis
  • Sartorius
  • Amgen
  • BeiGene
  • Bayer
  • TOT BIOPHARM
  • Henlius
  • Pfizer
  • Eli Lilly
  • Roche
  • Luye Pharmaceutical
  • Mylan
  • Qilu Pharmaceutical
  • Innovent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Avastin (Bevacizumab) Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Avastin (Bevacizumab) Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Avastin (Bevacizumab) Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Avastin (Bevacizumab) Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Avastin (Bevacizumab) Biosimilars Market Dynamics
  1. 2.1 Avastin (Bevacizumab) Biosimilars Industry Trends
  2. 2.2 Avastin (Bevacizumab) Biosimilars Industry Drivers
  3. 2.3 Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges
  4. 2.4 Avastin (Bevacizumab) Biosimilars Industry Restraints
3 Avastin (Bevacizumab) Biosimilars Market by Manufacturers
  1. 3.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Avastin (Bevacizumab) Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global Avastin (Bevacizumab) Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Avastin (Bevacizumab) Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Avastin (Bevacizumab) Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Avastin (Bevacizumab) Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global Avastin (Bevacizumab) Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Avastin (Bevacizumab) Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Avastin (Bevacizumab) Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Avastin (Bevacizumab) Biosimilars Tier 1, Tier 2, and Tier 3
4 Avastin (Bevacizumab) Biosimilars Market by Type
  1. 4.1 Avastin (Bevacizumab) Biosimilars Type Introduction
  2. 4.1.1 Cancers
  3. 4.1.2 AMD
  4. 4.2 Global Avastin (Bevacizumab) Biosimilars Sales by Type
  5. 4.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2021-2032)
  7. 4.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2021-2032)
  8. 4.3 Global Avastin (Bevacizumab) Biosimilars Revenue by Type
  9. 4.3.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2021-2032)
  11. 4.3.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2021-2032)
5 Avastin (Bevacizumab) Biosimilars Market by Application
  1. 5.1 Avastin (Bevacizumab) Biosimilars Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Avastin (Bevacizumab) Biosimilars Sales by Application
  6. 5.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2021-2032)
  8. 5.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2021-2032)
  9. 5.3 Global Avastin (Bevacizumab) Biosimilars Revenue by Application
  10. 5.3.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2021-2032)
  12. 5.3.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2021-2032)
6 Global Avastin (Bevacizumab) Biosimilars Sales by Region
  1. 6.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global Avastin (Bevacizumab) Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Avastin (Bevacizumab) Biosimilars Revenue by Region
  1. 7.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Region
  2. 7.1.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Avastin (Bevacizumab) Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Avastin (Bevacizumab) Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Avastin (Bevacizumab) Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocad
  2. 8.1.1 Biocad Company Information
  3. 8.1.2 Biocad Business Overview
  4. 8.1.3 Biocad Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio
  6. 8.1.5 Biocad Recent Developments
  7. 8.2 Biocon
  8. 8.2.1 Biocon Company Information
  9. 8.2.2 Biocon Business Overview
  10. 8.2.3 Biocon Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio
  12. 8.2.5 Biocon Recent Developments
  13. 8.3 Cadila Pharmaceuticals
  14. 8.3.1 Cadila Pharmaceuticals Company Information
  15. 8.3.2 Cadila Pharmaceuticals Business Overview
  16. 8.3.3 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio
  18. 8.3.5 Cadila Pharmaceuticals Recent Developments
  19. 8.4 Centus
  20. 8.4.1 Centus Company Information
  21. 8.4.2 Centus Business Overview
  22. 8.4.3 Centus Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Centus Avastin (Bevacizumab) Biosimilars Product Portfolio
  24. 8.4.5 Centus Recent Developments
  25. 8.5 Dr Reddy's
  26. 8.5.1 Dr Reddy's Company Information
  27. 8.5.2 Dr Reddy's Business Overview
  28. 8.5.3 Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio
  30. 8.5.5 Dr Reddy's Recent Developments
  31. 8.6 Genentech
  32. 8.6.1 Genentech Company Information
  33. 8.6.2 Genentech Business Overview
  34. 8.6.3 Genentech Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio
  36. 8.6.5 Genentech Recent Developments
  37. 8.7 Hetero
  38. 8.7.1 Hetero Company Information
  39. 8.7.2 Hetero Business Overview
  40. 8.7.3 Hetero Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio
  42. 8.7.5 Hetero Recent Developments
  43. 8.8 Kirin Biologics
  44. 8.8.1 Kirin Biologics Company Information
  45. 8.8.2 Kirin Biologics Business Overview
  46. 8.8.3 Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio
  48. 8.8.5 Kirin Biologics Recent Developments
  49. 8.9 MAbxience
  50. 8.9.1 MAbxience Company Information
  51. 8.9.2 MAbxience Business Overview
  52. 8.9.3 MAbxience Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio
  54. 8.9.5 MAbxience Recent Developments
  55. 8.10 PharmaPraxis
  56. 8.10.1 PharmaPraxis Company Information
  57. 8.10.2 PharmaPraxis Business Overview
  58. 8.10.3 PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio
  60. 8.10.5 PharmaPraxis Recent Developments
  61. 8.11 PlantForm
  62. 8.11.1 PlantForm Company Information
  63. 8.11.2 PlantForm Business Overview
  64. 8.11.3 PlantForm Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio
  66. 8.11.5 PlantForm Recent Developments
  67. 8.12 Samsung Bioepis
  68. 8.12.1 Samsung Bioepis Company Information
  69. 8.12.2 Samsung Bioepis Business Overview
  70. 8.12.3 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio
  72. 8.12.5 Samsung Bioepis Recent Developments
  73. 8.13 Sartorius
  74. 8.13.1 Sartorius Company Information
  75. 8.13.2 Sartorius Business Overview
  76. 8.13.3 Sartorius Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio
  78. 8.13.5 Sartorius Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 BeiGene
  86. 8.15.1 BeiGene Company Information
  87. 8.15.2 BeiGene Business Overview
  88. 8.15.3 BeiGene Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio
  90. 8.15.5 BeiGene Recent Developments
  91. 8.16 Bayer
  92. 8.16.1 Bayer Company Information
  93. 8.16.2 Bayer Business Overview
  94. 8.16.3 Bayer Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio
  96. 8.16.5 Bayer Recent Developments
  97. 8.17 TOT BIOPHARM
  98. 8.17.1 TOT BIOPHARM Company Information
  99. 8.17.2 TOT BIOPHARM Business Overview
  100. 8.17.3 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio
  102. 8.17.5 TOT BIOPHARM Recent Developments
  103. 8.18 Henlius
  104. 8.18.1 Henlius Company Information
  105. 8.18.2 Henlius Business Overview
  106. 8.18.3 Henlius Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio
  108. 8.18.5 Henlius Recent Developments
  109. 8.19 Pfizer
  110. 8.19.1 Pfizer Company Information
  111. 8.19.2 Pfizer Business Overview
  112. 8.19.3 Pfizer Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio
  114. 8.19.5 Pfizer Recent Developments
  115. 8.20 Eli Lilly
  116. 8.20.1 Eli Lilly Company Information
  117. 8.20.2 Eli Lilly Business Overview
  118. 8.20.3 Eli Lilly Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio
  120. 8.20.5 Eli Lilly Recent Developments
  121. 8.21 Roche
  122. 8.21.1 Roche Company Information
  123. 8.21.2 Roche Business Overview
  124. 8.21.3 Roche Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Roche Avastin (Bevacizumab) Biosimilars Product Portfolio
  126. 8.21.5 Roche Recent Developments
  127. 8.22 Luye Pharmaceutical
  128. 8.22.1 Luye Pharmaceutical Company Information
  129. 8.22.2 Luye Pharmaceutical Business Overview
  130. 8.22.3 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  132. 8.22.5 Luye Pharmaceutical Recent Developments
  133. 8.23 Mylan
  134. 8.23.1 Mylan Company Information
  135. 8.23.2 Mylan Business Overview
  136. 8.23.3 Mylan Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio
  138. 8.23.5 Mylan Recent Developments
  139. 8.24 Qilu Pharmaceutical
  140. 8.24.1 Qilu Pharmaceutical Company Information
  141. 8.24.2 Qilu Pharmaceutical Business Overview
  142. 8.24.3 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  144. 8.24.5 Qilu Pharmaceutical Recent Developments
  145. 8.25 Innovent
  146. 8.25.1 Innovent Company Information
  147. 8.25.2 Innovent Business Overview
  148. 8.25.3 Innovent Avastin (Bevacizumab) Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio
  150. 8.25.5 Innovent Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Avastin (Bevacizumab) Biosimilars Value Chain Analysis
  2. 9.1.1 Avastin (Bevacizumab) Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Avastin (Bevacizumab) Biosimilars Production Mode & Process
  6. 9.2 Avastin (Bevacizumab) Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Avastin (Bevacizumab) Biosimilars Distributors
  9. 9.2.3 Avastin (Bevacizumab) Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst